Literature DB >> 23529855

Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line.

Yizhong Wang1, Jieliang Li, Xu Wang, Li Ye, Yu Zhou, Rebecca M Thomas, Wenzhe Ho.   

Abstract

Toll-like receptor 3 (TLR3) activation plays an important role in the innate immune responses to viral infections. We show here that the activation of TLR3 signaling pathway by poly I:C, a synthetic mimic of dsRNA, could induce high-level expression of interferon (IFN)-λ1 in a hepatoma cell line. The induced IFN-λ1 contributed to poly I:C-mediated inhibition of hepatitis C virus (HCV) Japanese fulminant hepatitis-1 (JFH-1) replication in Huh7 cells. This inhibitory effect of poly I:C on HCV replication, however, was compromised by HCV infection of Huh7 cells. Investigation of the mechanisms showed that HCV infection suppressed the expression of poly I:C-induced IFN-λ1 and IFN-stimulated genes [IFN-stimulated gene 56 (ISG-56), myxovirus resistance A (MxA) and 2'-5'-oligoadenylate synthetase 1 (OAS-1))], the key antiviral elements in IFN signaling pathway. Among the HCV nonstructural (NS) proteins tested, NS3/4A, NS5A and NS5B had the ability to inhibit poly I:C-induced IFN-λ1 expression in Huh7 cells. These observations provide the experimental evidence that HCV and its proteins impair TLR3 signaling and inhibit intracellular IFN-λ1/ISG expression in a hepatoma cell line, which may account for HCV persistence in the liver.

Entities:  

Keywords:  Hepatitis C virus; IFN-stimulated genes; Toll-like receptor 3; interferon-λ; poly I:C

Mesh:

Substances:

Year:  2013        PMID: 23529855      PMCID: PMC3935718          DOI: 10.1177/1753425913478991

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  48 in total

Review 1.  Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties.

Authors:  K E Reed; C M Rice
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

Review 2.  Gene structure and function of the 2'-5'-oligoadenylate synthetase family.

Authors:  J Justesen; R Hartmann; N O Kjeldgaard
Journal:  Cell Mol Life Sci       Date:  2000-10       Impact factor: 9.261

Review 3.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 4.  Type III IFNs: new layers of complexity in innate antiviral immunity.

Authors:  Nina Ank; Søren R Paludan
Journal:  Biofactors       Date:  2009 Jan-Feb       Impact factor: 6.113

5.  Toll-like receptor 3 activation induces antiviral immune responses in mouse sertoli cells.

Authors:  Donatella Starace; Roberta Galli; Alessio Paone; Paola De Cesaris; Antonio Filippini; Elio Ziparo; Anna Riccioli
Journal:  Biol Reprod       Date:  2008-07-02       Impact factor: 4.285

Review 6.  Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection.

Authors:  A M Battaglia; K O Hagmeyer
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

7.  Innate immune responses in human monocyte-derived dendritic cells are highly dependent on the size and the 5' phosphorylation of RNA molecules.

Authors:  Miao Jiang; Pamela Osterlund; L Peter Sarin; Minna M Poranen; Dennis H Bamford; Deyin Guo; Ilkka Julkunen
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

8.  Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes.

Authors:  Kui Li; Zihong Chen; Nobuyuki Kato; Michael Gale; Stanley M Lemon
Journal:  J Biol Chem       Date:  2005-02-28       Impact factor: 5.157

9.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Authors:  Andrew J Muir; Mitchell L Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torre; Steven Flamm; Stuart C Gordon; Paul Marotta; John M Vierling; Juan Carlos Lopez-Talavera; Kelly Byrnes-Blake; David Fontana; Jeremy Freeman; Todd Gray; Diana Hausman; Naomi N Hunder; Eric Lawitz
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

10.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

View more
  9 in total

Review 1.  Immune and non-immune responses to hepatitis C virus infection.

Authors:  Jiaren Sun; Ricardo Rajsbaum; MinKyung Yi
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Toll-like receptor 3-activated macrophages confer anti-HCV activity to hepatocytes through exosomes.

Authors:  Yu Zhou; Xu Wang; Li Sun; Li Zhou; Tong-Cui Ma; Li Song; Jian-Guo Wu; Jie-Liang Li; Wen-Zhe Ho
Journal:  FASEB J       Date:  2016-09-07       Impact factor: 5.191

Review 3.  The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections.

Authors:  Adrian Egli; Deanna M Santer; Daire O'Shea; D Lorne Tyrrell; Michael Houghton
Journal:  Emerg Microbes Infect       Date:  2014-07-16       Impact factor: 7.163

4.  (-)-Epigallocatechin-3-Gallate Enhances Hepatitis C Virus Double-Stranded RNA Intermediates-Triggered Innate Immune Responses in Hepatocytes.

Authors:  Yizhong Wang; Jieliang Li; Xu Wang; Juliet C Peña; Kui Li; Ting Zhang; Wenzhe Ho
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

5.  (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes.

Authors:  Yi-Zhong Wang; Jie-Liang Li; Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

6.  TIR-Domain-Containing Adapter-Inducing Interferon-β (TRIF)-Dependent Antiviral Responses Protect Mice against Ross River Virus Disease.

Authors:  Xiang Liu; Adam Taylor; Yee Suan Poo; Wern Hann Ng; Lara J Herrero; Patrick Chun Hean Tang; Ali Zaid; Suresh Mahalingam
Journal:  mBio       Date:  2022-01-04       Impact factor: 7.867

7.  Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.

Authors:  Jun Itakura; Masayuki Kurosaki; Mayu Higuchi; Hitomi Takada; Natsuko Nakakuki; Yoshie Itakura; Nobuharu Tamaki; Yutaka Yasui; Shoko Suzuki; Kaoru Tsuchiya; Hiroyuki Nakanishi; Yuka Takahashi; Shinya Maekawa; Nobuyuki Enomoto; Namiki Izumi
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

8.  Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity.

Authors:  Surasak Jittavisutthikul; Watee Seesuay; Jeeraphong Thanongsaksrikul; Kanyarat Thueng-In; Potjanee Srimanote; Rolf G Werner; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2016-08-26       Impact factor: 7.561

9.  Intrahepatic TLR3 and IFNL3 Expressions Are Associated with Stages of Fibrosis in Chronic Hepatitis C.

Authors:  Keyla Santos Guedes de Sá; Ednelza da Silva Graça Amoras; Simone Regina Souza da Silva Conde; Maria Alice Freitas Queiroz; Izaura Maria Vieira Cayres-Vallinoto; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.